Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.

Applied biochemistry and biotechnology - 1 Mar 2010

Rajasekaran R, Sethumadhavan Rao

Abstract excerpt

In this work, we identified the detrimental missense mutations (point mutations) in epidermal growth factor receptor (EGFR) and its binding efficiency with the inhibitors namely Erlotinib, Gefitinib, and Lapatinib. Out of 26 point mutations on EGFR, 12 point mutations were commonly less stable, deleterious, and damaged as shown by all the three servers, I-Mutant2.0, SIFT, and PolyPhen. Further, we modeled 12...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Biology
Share to Databases, Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Mutant Proteins

Share to Protein Kinase Inhibitors

Share to Protein Structure, Secondary

Share to Quinazolines

Share to Software

Source

Identifiers

PMID: 19455431
DOI: 10.1007/s12010-009-8662-4

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.PMID 19455431Read ↗

Structural investigation of deleterious non-synonymous SNPs of EGFR gene.Semantic proximity Read ↗

Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.Semantic proximity Read ↗

Computational Prediction of Resistance Induced Alanine-Mutation in ATP Site of Epidermal Growth Factor Receptor.Semantic proximity Read ↗

A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.Semantic proximity Read ↗

Towards identification of novel inhibitors of EGFR mutants through in-silico approach.Semantic proximity Read ↗

Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer.Semantic proximity Read ↗

<i>In Vitro</i> Validation of Computationally Predicted Oncogenic Driver Mutations in EGFR Tyrosine Kinase DomainSemantic proximity Read ↗

Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors.Semantic proximity Read ↗

Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.Semantic proximity Read ↗

Systematic molecular profiling of inhibitor response to the clinical missense mutations of ErbB family kinases in human gastric cancer.Semantic proximity Read ↗

Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).Semantic proximity Read ↗

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.